Literature DB >> 17686550

Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues.

Ryo Morimoto1, Fumitoshi Satoh, Osamu Murakami, Kazuhito Totsune, Yoichi Arai, Takashi Suzuki, Hironobu Sasano, Sadayoshi Ito, Kazuhiro Takahashi.   

Abstract

Urotensin II (UII), first identified from goby urophysis, is a potent vasoactive peptide hormone and an endogenous ligand for an orphan G protein-coupled receptor GPR14, now named urotensin II receptor (UT-R). In addition to its vascular actions, UII has been shown to have mitogenic effects on tumor growth and some regulatory effects on adrenal steroidogenesis. In the present study, we examined expression of UII and UT-R in human adrenal tumors and attached non-neoplastic adrenal tissues by immunohistochemistry. Both UII and UT-R were immunolocalized in tumor cells of all adrenal tumors examined: 8 cases of cortisol-producing adenomas, 8 cases of aldosterone-producing adenomas, 2 cases of non-functioning adenomas, 17 cases of adrenocortical carcinomas, and 8 cases of pheochromocytomas. In attached adrenals, immunoreactivity for UII was detected in medulla, but much weaker in the cortex than in cortical tumors, suggesting that expression of UII was up-regulated in neoplastic adrenocortical tissues. No significant differences were found in the degree of immunoreactivity for UT-R between the tumors and the attached adrenal tissues. The present study showed that both UII and UT-R were expressed in the adrenal tumors and attached non-neoplastic adrenal tissues, and suggests possible roles of UII and UT-R in tumor growth and/or secretory activities of these tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686550     DOI: 10.1016/j.peptides.2007.06.025

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.

Authors:  Kazuhiro Takahashi; Itaru Shoji; Akiko Shibasaki; Ichiro Kato; Keisuke Hiraishi; Hajime Yamamoto; Kiriko Kaneko; Osamu Murakami; Ryo Morimoto; Fumitoshi Satoh; Sadayoshi Ito; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2009-11-07       Impact factor: 3.444

Review 3.  Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.

Authors:  Kazuhiro Takahashi; Ryo Morimoto; Takuo Hirose; Fumitoshi Satoh; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2010-07-02       Impact factor: 3.444

4.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

Review 5.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

6.  Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.

Authors:  Renato Franco; Silvia Zappavigna; Vincenzo Gigantino; Amalia Luce; Monica Cantile; Margherita Cerrone; Gaetano Facchini; Sisto Perdonà; Sandro Pignata; Giuseppe Di Lorenzo; Sergio Chieffi; Giovanni Vitale; Marco De Sio; Alessandro Sgambato; Gerardo Botti; Ali Munaim Yousif; Ettore Novellino; Paolo Grieco; Michele Caraglia
Journal:  J Exp Clin Cancer Res       Date:  2014-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.